Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer - Related Studies

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer

This study is currently recruiting participants.

Study NCT00286793. Last updated on September 19, 2008. Information provided by Ascenta Therapeutics

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Prostate Cancer

2	Additional conditions recognized in this trial
		Prostatic Neoplasms

3	More general conditions related to this trial
		Genital Diseases, Male
		Genital Neoplasms, Male
		Neoplasms
		Neoplasms by Site
		Prostatic Diseases
		Urogenital Neoplasms

4	Interventions listed in this trial
		AT-101
		Docetaxel
		Prednisone

5	Additional drug interventions recognized in this trial
		Gossypol

6	More general drug interventions related to this trial
		Anti-Inflammatory Agents
		Antineoplastic Agents
		Antineoplastic Agents, Hormonal
		Contraceptive Agents
		Contraceptive Agents, Male
		Glucocorticoids
		Hormones
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Reproductive Control Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Ascenta Therapeutics